Stock CU6 CLARITY PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Clarity Pharmaceuticals Ltd

Equities

CU6

AU0000165375

Delayed Australian S.E.
Other stock markets
 12:05:21 2024-07-17 am EDT 		5-day change 1st Jan Change
5.84 AUD -0.17% Intraday chart for Clarity Pharmaceuticals Ltd +14.73% +207.37%
Jun. 24 Clarity Pharmaceuticals Receives AU$10 Million R&D Tax Refund MT
Jun. 07 Clarity Pharmaceuticals Confirms Isotope Supply Continuity for Clinical Trials MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Clarity Pharmaceuticals Receives AU$10 Million R&D Tax Refund
MT
Clarity Pharmaceuticals Confirms Isotope Supply Continuity for Clinical Trials
MT
Clarity Pharmaceuticals Signs Supply Deal for Copper Isotope
MT
Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes
MT
Clarity Pharmaceuticals to Raise AU$121 Million via Fully Underwritten Equity Raising
MT
Clarity Pharmaceuticals' SECuRE Trial Treats First Participant in Last Dose Escalation Cohort; Shares Down 5%
MT
Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial
CI
Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range
CI
Clarity Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA
CI
Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer
CI
Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level
CI
Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE
CI
Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial
CI
Clarity Pharmaceuticals and PSI CRO AG Kick Off SAR-BispsMA Phase III
CI
Clarity Pharmaceuticals Announces the Dosing of the First Patient in Its Theranostic (64) Cu Sar-Bombesin Phase I/Ii Trial in Metastatic Castrate Resistant Prostate Cancer Trial in Metastatic Castrates Resistant Prostate Cancer
CI
Clarity Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Clarity Pharmaceuticals Announces Successful Completion of Cohort 2 and Advancement to Cohort 2 of Theranostic Trial, Secure
CI
Clarity Pharmaceuticals Announces Phase II US-Based Diagnostic Cu SAR-Bombesin
CI
Clarity Pharmaceuticals Announces Positive Guidance from US FDA on Cu-64 Sar-Bispsma Phase III Trial in Prostate Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CU6 Stock
  4. News Clarity Pharmaceuticals Ltd
  5. Highlights